KYMR

Kymera Therapeutics, Inc.

Healthcare · Biotechnology

$286.66 sample

+5.12 (+1.82%) 1D

Market cap

$301.6B

Price as of

2026-10-15

Latest filing

8-K · 2026-08-26

Alerts

8

Price$286.66 +8.06% 3M daily closessample

296.61260.73

2026-07-202026-08-112026-09-022026-09-232026-10-15

purchase / approvalsale / rejectionfiling / neutral

Latest events

Filings, trades, FDA; newest first

Oct 09INSInsider sell: Director
Oct 01INSInsider buy: Director
Sep 28INSInsider sell: Chief Executive Officer
Sep 17INSInsider buy: 10% owner
Sep 08INSInsider buy: EVP, Operations
Aug 31INSInsider buy: 10% owner
Aug 26SECForm 144 filed
Aug 20SEC10-Q filed

Sign up to see the real KYMR record →

Company facts

SEC EDGAR registration

Name: Kymera Therapeutics, Inc.
Sector: Healthcare
Industry: Biotechnology
Smart-money score: -12sample, -100 to +100
Reporting currency: USD

Who is positioning in KYMR

sample

Insiders: 24 insider transactions over 90 days, net selling, $432.8M
Congress: 3 members traded over 90 days
Institutions · 13F: 31 funds hold $5.3B
Activists · 13D/G: No 13D/13G activist filings on record

How are the fundamentals trending?

sample, by period end

Revenue$19.4B +14.8% y/y

Q4 2024Q3 2026

Inventory$11.9B +16.6% y/y

Q4 2024Q3 2026

Accounts receivable$8.6B +9.5% y/y

Q4 2024Q3 2026

Total debt$22.2B +5.8% y/y

Q4 2024Q3 2026

Peers

sample

Sample peer A: $221.4B -1.9% 3M
Sample peer B: $227.5B +6.1% 3M
Sample peer C: $193.9B -1.9% 3M
Sample peer D: $83.1B +3.4% 3M
Sample peer E: $223.1B +5.1% 3M